GSK’s Zejula reduces risk of progression and death in mesothelioma study
GSK’s Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led…
News
Boehringer, Oxford University and Cumulus to explore brain activity in BPD
Trump’s first 100 days tout US-bound pharma investments amid tariff worries
Donald Trump’s first 100 days: Impact on the healthcare industry
FDA approves AbbVie’s upadacitinib for giant cell arteritis
FDA approves Abeona’s $3.1m cell therapy for rare skin disease
AstraZeneca’s Truqap fails in another Phase III trial
Construction begins on MSD’s $1bn biologics centre in Delaware, US
